At a glance
Effects
- Lean muscle gain: Dose-dependent increases in lean body mass were confirmed in a placebo-controlled trial (avg. +1.21 kg at 1 mg/day over 21 days) [1].
- Strength & power: Improvements in muscle strength and stair-climbing power were observed in clinical trial participants [1].
- Bone support: Pre-clinical data show increased bone mineral density, periosteal bone formation, and femur bending strength [1].
- Testosterone suppression: LGD-4033 suppresses total testosterone, SHBG, LH, and FSH in a dose-dependent manner; effects reversed within ~5 weeks of stopping [1][6].
- HDL cholesterol reduction: Significant suppression of HDL cholesterol was observed at the 1 mg dose; levels returned to baseline after cessation [1].
SARM (non-steroidal)
24–36 hours (oral)
Oral
Not FDA-approved; investigational only
Parent: ~7 days; metabolites: ~21 days (urine)
About LGD-4033
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
How it works
LGD-4033 binds to androgen receptors with high affinity and selectivity (Ki ≈ 0.9 nM), preferentially activating receptors in muscle and bone tissue while sparing the prostate and sebaceous glands [1][4]. As a non-steroidal ligand, it repositions helix 12 of the androgen receptor differently from testosterone, recruiting a distinct coregulator profile that drives anabolic signalling in target tissues without fully replicating the broad androgenic effects of testosterone [4]. Because LGD-4033 does not aromatise to oestrogen, its use reduces endogenous testosterone, which can secondarily lower oestrogen levels [5].
Risks & side effects
Most important: LGD-4033 causes dose-dependent suppression of endogenous testosterone, LH, and FSH, and reduces HDL cholesterol — both of which carry potential cardiovascular and endocrine consequences with longer or higher-dose use [1][6]. Separately, case reports document severe drug-induced liver injury (DILI), including cholestatic hepatitis with fibrosis, at the higher doses commonly used outside clinical trials [7][8].
Common
Serious
- Drug-induced liver injury (DILI) / cholestatic hepatitis — reported at high recreational doses [7][8]
- Cardiovascular risk: sustained HDL suppression may increase atherogenic risk with long-term use [1]
- Endocrine disruption: suppression of the HPG axis with potential for prolonged hypogonadism if used at high doses [6]
- Potential increased risk of heart attack and stroke (FDA warning for SARMs as a class) [3]
Safety & harm reduction
- Pregnancy or breastfeeding (unknown foetal/neonatal risk)
- Women of childbearing potential (virilisation risk; poorly characterised) [3]
- Pre-existing liver disease (DILI risk at higher doses) [7][8]
- Existing cardiovascular disease or dyslipidaemia (HDL suppression, potential CV risk) [1][3]
- Competitive athletes subject to WADA testing — banned under S1.2 Other Anabolic Agents [3]
- Persons under 21 years of age (HPG axis not fully mature)
- Baseline and on-cycle lipid panel (HDL, LDL, triglycerides) — HDL suppression documented even at 1 mg/day [1]
- Liver function tests (AST, ALT, bilirubin) — DILI reported with higher recreational doses [7][8]
- Total testosterone, free testosterone, LH, FSH — suppression confirmed; monitor recovery post-cycle [1][6]
- Blood pressure monitoring throughout cycle
- Other hepatotoxic compounds (oral 17α-alkylated steroids, alcohol, acetaminophen) — additive liver stress risk [7]
- Other androgens or anabolic agents — additive HPG axis suppression
- Anticoagulants — androgen receptor agonists may alter clotting parameters; monitor INR if applicable
- CYP3A4 substrates / inhibitors — SARM metabolism pathway; interactions not well characterised in humans
- Due to significant testosterone suppression, a post-cycle therapy (PCT) protocol (e.g., SERMs such as nolvadex/clomid) is commonly used by practitioners after cycles to aid HPG axis recovery [1][6]
- Given documented DILI risk at recreational doses, liver-support supplements (TUDCA, NAC) are often co-administered, though their efficacy in this context is unproven
- Avoid stacking with other hepatotoxic compounds
- Long-term safety is not established; limit cycle length conservatively [9]
Dosage context
Clinical trials used repeated doses of 0.1–2 mg/day for 3–12 weeks [4]. Black-market, non-medical use is commonly reported at 5–10 mg/day — 5 to 100 times the studied range — with unknown safety implications at those doses [4]. No safe or effective dose for non-medical use has been established. These figures are reported for harm-reduction context only and do not constitute a prescription or recommendation.
Sources
- 1.Basaria et al. (2013) — Phase 1 RCT, PMC
- 2.Basaria et al. (2013) — PubMed abstract
- 3.USADA — 5 Things to Know about LGD-4033
- 4.Wikipedia — LGD-4033
- 5.Fit Science — LGD-4033 Complete Guide
- 6.SelfDecode — Ligandrol Side Effects & Dangers
- 7.ACG Case Reports Journal — LGD-4033-Induced Liver Injury
- 8.Cureus — LGD-4033 and Drug-Induced Liver Injury (PMC)
- 9.ChemicalBook — LGD-4033 SARM overview
- 10.LotiLabs — LGD-4033 Pharmacokinetics Research Guide 2026
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for LGD-4033· 4 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
This compound comes in different forms (e.g. injectable vs oral vs topical). Cost per mg is only comparable within the same form.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
Intex PharmaSelected | blister-pack | 10 mg/tab | 60 tab | 84,90 € | ★€0.142/mg |
Generic | blister-pack | 10 mg/tab | 30 tab | 94,90 € | €0.316/mg |
Generic | oral-liquid | 20 mg/ml | 50 ml | 129,99 € | €0.130/mg |
Generic | oral-liquid | 20 mg/ml | 100 ml | 219,99 € | ★€0.110/mg |